MedTrace Logo

Intermittent Levetricetam in Treatment of Febrile Convulsions

NCT05860153 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2023-05-16

No results posted yet for this study

Summary

The American Academy of Pediatrics (AAP) in 2011 published a clinical practice guideline defining a febrile seizure as "a seizure accompanied by fever (temperature ≥ 100.4°F or 38°C by any method), without central nervous system infection, that occurs in infants and children 6 through 60 months of age." Febrile seizures are further classified as simple (generalized in onset, last less than 15 minutes, and do not occur more than once in 24 hours.) or complex (FS duration longer than 15 min, repeated convulsions within the same day, and focal seizure activity or focal findings during the postictal period.).

Conditions

  • Febrile Convulsion

Interventions

DRUG

Levetiracetam

Group with oral levetiracetam at a dose of 15-20 mg/kg/day

DRUG

Diazepam

Group with diazepam at a dose of 0.3 mg/kg/dose

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • Khaled Elsayah, Prof · Assiut University

  • Khalaf Abd El-Aal, Assist prof · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Months
Max Age
36 Months
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-06-01
Primary Completion
2024-01-01
Completion
2024-08-01

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05860153 on ClinicalTrials.gov